A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization
There is uncertainty in cardiologists’ attitudes for prolonging dual antiplatelet therapy (DAPT) with ticagrelor 60 mg beyond 12 months in post-myocardial infarction (MI) patients. We aimed at characterizing the Italian cardiologists’ perceptions and needs in the management of such patients. Two con...
Main Authors: | Raffaele De Caterina, Paolo Calabrò, Gianluca Campo, Roberta Rossini, Simona Giubilato |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/8/2091 |
Similar Items
-
PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW
by: I. S. Yavelov
Published: (2017-09-01) -
Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events?
by: O. L Barbarash, et al.
Published: (2015-06-01) -
Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01) -
Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock
by: Wiktor Kuliczkowski, et al.
Published: (2020-12-01) -
Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study
by: Luigi Fiocca, et al.
Published: (2022-10-01)